10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Diagnosis, prognosis and therapeutic role of circulating miRNAs in cardiovascular diseases.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality in the world. Although much progress has been made for cardiovascular diseases in diagnosis, treatment and prognosis during the past two decades, the clinical need for a novel diagnostic biomarker and new therapeutic interventions to decrease the cardiovascular disease incidence is ongoing. MicroRNAs (miRNAs) are endogenous, small (∼22 nucleotides), single-stranded, non-coding RNAs that regulate gene expression and are detectable in whole blood, serum, plasma, urine and other body fluids in a highly stable form. Accumulating evidence suggests that miRNAs are potential novel biomarkers with high sensitivity for early diagnosis and modern treatment for cardiovascular diseases. Altered circulating miRNAs expressions have been reported in acute myocardial infarction (AMI), acute coronary syndrome (ACS), stable coronary artery disease, heart failure, atherosclerosis, essential hypertension and stroke. In the present review, we examine more recent data regarding circulating miRNAs and their potential roles in diagnosis, prognosis and therapeutic strategies for cardiovascular diseases. In addition, we briefly present our own recent experience in detecting circulating miRNAs, and the significance of these miRNAs in AMI prognosis.

          Related collections

          Author and article information

          Journal
          Heart Lung Circ
          Heart, lung & circulation
          Elsevier BV
          1444-2892
          1443-9506
          Jun 2014
          : 23
          : 6
          Affiliations
          [1 ] Department of Cardiology, Xiangya Hospital, Central South University, Changsha 410078, China.
          [2 ] Department of Cardiology, Xiangya Hospital, Central South University, Changsha 410078, China; Center for Vascular Biology and Inflammation, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, U.S.A.
          [3 ] Department of Obstetrics and Gynecology, Xiangya 3(rd) Hospital, Central South University, Changsha 410013, China.
          [4 ] Department of Cardiology, Xiangya Hospital, Central South University, Changsha 410078, China. Electronic address: tianluny@163.com.
          [5 ] Department of Pharmacology, School of Pharmaceutical Sciences, Central South University, Changsha 410078, China. Electronic address: Junpeng@csu.edu.cn.
          Article
          S1443-9506(14)00030-4
          10.1016/j.hlc.2014.01.001
          24726001
          b66b4d7c-ef58-4088-9762-939b63d4cc38
          History

          Biomarkers,Cardiovascular disease (CVD),Circulating miRNAs,Prognosis,Treatment

          Comments

          Comment on this article